Systemic administration of anti–miR-17 alleviates proteinuria. BALB/c mice were lethally irradiated and transferred with 5 × 10⁶ TCD-BM cells (Ly5.1⁺), plus 30 × 10⁶ luciferase-transduced CD25⁻ splenocytes (Ly5.2⁺) from DBA2 mice. Recipient mice were treated with individual antagomirs as indicated at a loading dose 25 mg/kg at day 0 followed by 5 mg/kg twice weekly up to day 25 after BMT. The clinical score (A) and proteinuria/ascites incidence (B) on indicated days after BMT are shown. The expansion of injected donor splenocytes was monitored by using BLI, and data are presented as mean signal intensity (C). Sixty days after BMT, serum TNFα (D), percentage of GL-7⁺Fas⁺ GC B cells on gated live B220⁺ cells, and B220⁻CD138⁺ plasma cells on gated live cells in spleen (E) are shown. (F) MFI of MHC-II (IA^d) and CD86 on donor CD5.1⁺B220⁺ cells in spleen are shown 60 days after BMT. N = 7 mice per group. *P < .05; **P < .01; ***P < .001. P values denote comparison between scrambled and anti–miR-17 in panels B and C.